On March 13, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, and its subsidiary, Jinzhou Avanc Pharma Limited Liability Company (hereinafter referred to as Avanc Pharma), jointly developed the application for registration of Aripiprazole Oral Solution (trade name: Anxinqi®). The application for marketing registration of aripiprazole oral solution (trade name: Anxinqi®) jointly developed by Aohong Pharmaceutical Co.

The drug is used for the treatment of schizophrenia in adolescents and adults aged 13 to 17 years old. Compared with other psychotropic drugs, it has the advantages of less side effects, significant efficacy, low relapse rate, etc. It is suitable for the long-term treatment of schizophrenia patients with a full course of disease, and it is the first-line anti-schizophrenia drug recommended by many domestic and foreign guidelines.

Compared with oral solid preparation, oral solution has good fluidity, easy to take, precise and convenient dosage adjustment, which is more suitable for patients who have difficulty in taking medication and have high demand for dosage adjustment, and can improve patients' medication compliance.

Schizophrenia is a group of serious mental illnesses of unknown etiology, most often starting in young adults, often with perception, thinking, emotion and behavioral disorders, usually without consciousness and intellectual disability. Schizophrenia is the leading cause of mental disability, imposing a huge emotional, health, social and economic burden on patients, families, caregivers and society. According to epidemiologic surveys, there are about 24 million people with schizophrenia worldwide and about 8 million people with schizophrenia in China.

According to the latest data of IQVIA CHPA, the sales of aripiprazole preparation in China will be about RMB 823 million in 2022, and the drug has a very broad market prospect with the deepening of clinical application.

Avanc Pharma has long been focusing on the neurological field, focusing on unmet clinical needs, actively laying out its R&D pipeline, and committing itself to bringing new hope to patients' health. The approval of this drug not only further enriches the product pipeline, but also provides more and better solutions for the treatment of schizophrenia.

https://mp.weixin.qq.com/s?__biz=MjM5NTM3OTYwNA==&mid=2650490680&idx=2&sn=90af856ae2a0ebddf71ec68c3abe1a6f&chksm=bef687c389810ed5d056b12ea1513cbb7bf2617c9a382b81723afa60d044e6289637aa9893d9&mpshare=1&scene=1&srcid=0315CQQKFUIVjUW8GIsS6De0&sharer_shareinfo=e7dfa290e4efc21bb32bcb4cad10f87e&sharer_shareinfo_first=e7dfa290e4efc21bb32bcb4cad10f87e#rd